Optimizing transdermal drug therapy

American Journal of Health-System Pharmacy

Volumn 65, Issue 14, 2008, Pages 1337-1346

  Ball, Amanda M ^a   Smith, Kelly M ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b University of Kentucky   (United States)

Author keywords

Adhesion; Adhesives; Patches transdermal; Stability; Storage; Toxicity

Indexed keywords

ADHESIVE AGENT; BENGAY; CAMPHOR; CLONIDINE; CONTRACEPTIVE AGENT; DICLOFENAC; ESCLIM; ESTRADIOL; ESTRADIOL PLUS LEVONORGESTREL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORELGESTROMIN; FENTANYL; GLYCERYL TRINITRATE; IONSYS; LACTIC ACID PLUS SALICYLIC ACID; LIDOCAINE; LIDOCAINE PLUS TETRACAINE; MENTHOL; METHYLPHENIDATE; NICOTINE; OXYBUTYNIN; RIVASTIGMINE; ROTIGOTINE; SALICYLIC ACID; SCOPOLAMINE; SELEGILINE; SYNERA; TESTOSTERONE; TRANSVER SAL; TRIAMINIC; TRIAMINIC VAPOR PATCH;

ADHESION; CAREGIVER; CONTACT SENSITIZATION; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG LABELING; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICATION ERROR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COUNSELING; PATIENT GUIDANCE; PATIENT SATISFACTION; PHYSICIAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN TEMPERATURE; STRATUM CORNEUM; TRANSDERMAL DRUG ADMINISTRATION; TRANSDERMAL PATCH; TREATMENT RESPONSE; COUNSELING; DRUG TOXICITY; INTRADERMAL DRUG ADMINISTRATION; PHARMACOKINETICS; RISK ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; COUNSELING; DRUG TOXICITY; HUMANS; MEDICATION ERRORS; PHARMACOKINETICS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 47749121429     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070554     Document Type: Review

References (61)

1. CBS News. Birth control patch users warned. www.cbsnews.com/v stories/2005/11/11/earlyshow/health/health_news/main1037611_page2.shtml (accessed 2006 Jul 2).
2. Fallik D. Experts: patches + heat = danger. Phila Inquirer. 2006; Mar 5:A1.
3. Morrow T. Transdermal patches are more than skin deep. www.managedcaremag.com/archives/0404/0404.biotech.html (accessed 2006 Mar 7).
4. Schulmeister L. Transdermal drug patches: medicine with muscle. Nursing. 2005; 35:48-52.
5. Oxytrol (oxybutynin transdermal system) product information. Corona, CA: Watson Pharma Inc.; 2003 Feb.
6. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004; 3:115-24.
7. The United States pharmacopeia, 23rd rev., and The national formulary, 18th ed. Rockville, MD: United States Pharmacopeial Convention; 1994:15-1647.
8. Duragesic (fentanyl transdermal system) product information. Titusville, NJ: Janssen Pharmaceutica Products L.P. Inc.; 2005 Feb.
9. Klockgether-Radke A, Heldebrandt J. [Opioid intoxication. Inappropriate administration of transdermal fentanyl.] Anaesthesist. 1997; 46:428-9. In German.
10. Broderick-Cantwell JJ. Case study: accidental clonidine patch overdose in attention-deficit/hyperactivity disorder patients. J Am Acad Child Adolesc Psychiatry. 1999; 38:95-8.
11. Roberge RJ, Krenzelok EP, Mrvos T. Transdermal drug delivery system exposure outcomes. J Emerg Med. 2000; 18:147-51.
12. Catapres-TTS (clonidine transdermal therapeutic system) package insert. Ridgefield, CT: Boehringer Ingelheim; 2004 Aug.
13. Lee TW, Robinson J. Controlled-release drug delivery systems. In: Gennaro AR, Der Marderosian AH, Hanson GR et al., eds. Remington: the science and practice of pharmacy. 20th ed. Baltimore: Lippincott Williams & Wilkins; 2000:917-8.
14. Flector (diclofenac epolamine topical patch) prescribing information. Huntington Beach, CA: Instituto Biochimique SA; 2007 Jan.
15. Alora (estradiol transdermal system) prescribing information. Corona, CA: Watson Pharmaceuticals; 2005 May.
16. Climara (estradiol transdermal system) prescribing information. Montville, NJ: Berlex; 2005 Jul.
17. Ankarberg-Lindgren C, Elfving M, Albertsson Wikland K et al. Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. J Clin Endocrinol Metab. 2001; 86:3039-44.
18. Marty JP. New trends in transdermal technologies: development of the skin patch, Menorest. Int J Gynaecol Obstet. 1996; 52(suppl 1):S17-20.
19. Esclim (estradiol transdermal system continuous delivery for twice-weekly application) prescribing information. Randolph, MA: Women First HealthCare Inc.; 1999 Jul.
20. Estraderm (estradiol transdermal system) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals; 2005 Jan.
21. Menostar (estradiol transdermal system) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals; 2006 Aug.
22. Vivelle (estradiol transdermal system) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals; 2004 Aug.
23. Vivelle-Dot (estradiol transdermal system) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals; 2004 Aug.
24. ClimaraPro (estradiol/levonorgestrel transdermal system) prescribing information. Montville, NJ: Berlex; 2003 Nov.
25. Combipatch (estradiol/norethindrone acetate transdermal system) prescribing information. Miami, FL: Novartis Pharmaceuticals; 2005 Jan.
26. Ortho Evra (norelgestromin/ethinyl estradiol transdermal system) prescribing information. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc.; 2005 Nov.
27. Ionsys (fentanyl iontophoretic transdermal system) prescribing information (draft). www.fda.gov/cder/foi/label/2006/0213381bl.pdf (accessed 2006 Jun 7).
28. Lidoderm (lidocaine patch 5%) prescribing information. Chadds Ford, PA: Endo Pharmaceuticals; 2005 Aug.
29. Cada DJ, Arnold B, Levien T et al. Lidocaine/tetracaine patch. Hosp Pharm. 2006; 41:265-71.
30. Minitran (nitroglycerin transdermal delivery system) prescribing information. Northridge, CA: 3M Pharmaceuticals; 1999 May.
31. Nitro-Dur (nitroglycerin transdermal infusion system) prescribing information. Kenilworth, NJ: Key Pharmaceuticals; 2004 Dec.
32. Paloni JA, Appleyard RC, Nelson J et al. Topical glyceryl trinitrate for chronic achilles tendinopathy. J Bone Joint Surg. 2004; 86:916-22.
33. Daytrana (methylphenidate transdermal system) prescribing information. Wayne, PA: Shire Pharmaceuticals; 2006 Apr.
34. Exelon patch (rivastigmine transdermal system) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals; 2007 Jul.
35. Neupro (rotigotine transdermal system) prescribing information. Mequon, WI: Schwarz Pharma; 2006 Jun.
36. Emsam (selegiline transdermal system) prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2006 Feb.
37. Androderm (testosterone transdermal system) prescribing information. Corona, CA: Watson Pharmaceuticals Inc.; 2001 Jun.
38. Food and Drug Administration. FDA warns consumers not to use Triaminic Vapor Patch, possible safety and health risks to children. www.fda.gov/bbs/ topics/NEWS/2006/NEW01392.html (accessed 2006 Jun 20).
39. GlaxoSmithKline. Frequently asked questions: Nicoderm CQ (nicotine transdermal system). www.nicodermcq.com/Faqs.aspx (accessed 2006 Jul 2).
40. Habitrol (nicotine) product information. Miami, FL: Novartis Pharmaceuticals Corporation; 2006.
41. BenGay pain relieving patch (menthol) product information. New York: Pfizer Consumer Healthcare; 2005.
42. Trans-ver-sal (salicylic acid 15%) product information. Fairfield, NJ: Bradley-Kenwood Labs; 2005.
43. Transderm Scōp (scopolamine) product information. Parsippany, NJ: Novartis Pharmaceuticals; 2004.
44. Williams AC. Transdermal and topical drug delivery: from theory to clinical practice. London: Pharmaceutical Press; 2003:178-83.
45. Wong NN, Chen JL, Luks-Golger D. Absorption of clonidine from a halved transdermal system - a pilot study. J Pharm Technol. 2001; 17:84-9.
46. Zuppa AF, Tejani SM, Cullen EJ et al. Plasma concentrations following application of whole versus cut transdermal clonidine patches to critically ill children. J Pediatr Pharmacol Ther. 2004; 91:43-8.
47. Food and Drug Administration. FDA alert: narcotic overdose and death - fentanyl transdermal system (marketed as Duragesic). www.fda.gov/cder/drug/ InfoSheets/HCP/fentanylHCP.htm (accessed 2006 Mar 7).
48. Teske J, Weller JP, Larsch K et al. Fatal outcome in a child after ingestion of a transdermal fentanyl patch. Int J Legal Med. 2007; 121:147-51.
49. Food and Drug Administration. Announcement of revised labeling for Ortho Evra (norelgestromin/ethinyl estradiol). www.fda.gov/cder/drug/infopage/ orthoevra/qa.htm (accessed 2006 May 20).
50. Schmid RE. Study: patch is riskier than pill contraceptive. www.philly.com/mld/inquirer/living/health/13901817.htm (accessed 2006 Mar 7).
51. Jick SS, Jick H. The contraceptive patch in relation to ischemic stroke and acute myocardial infarction. Pharmacotherapy. 2007; 27:218-20.
52. Transdermal methylphenidate (Daytrana) for ADHD. Med Lett Drugs Ther. 2006; 48:49-51.
53. Parker & Waichman, LLP. Injured by the Duragesic patch? www.yourlawyer.com/topics/overview/duragesic_patch/ (accessed 2006 Mar 7).
54. Parker & Waichman, LLP. Transdermal patches: an innovative drug delivery system that has raised serious safety concerns. www.yourlawyer.com/ articles/read/11450/ (accessed 2006 Mar 7).
55. Lee M, Phillips J. Transdermal patches; high risk for error? Drug Topics. 2002; 146(7):54-5.
56. Institute for Safe Medication Practices. More problems with patches. Pharm Today. 2006; 12:76.
57. Frolich MA, Giannotti A, Modell JH. Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg. 2001; 93:647-8.
58. Rose PG, Macfee MS, Boswell MV. Fentanyl transdermal system overdose secondary to cutaneous hyperthermia. Anesth Analg. 1993; 77:390-1.
59. Institute for Safe Medication Practices. New fentanyl warnings: more needed to protect patients. www.ismp.org/Newsletters/acutecare/articles/ 20050811.asp?ptr=y (accessed 2008 Apr 14).
60. Edinboro LE, Poklis A, Trautman D et al. Fatal fentanyl intoxication following excessive transdermal application. J Forensic Sci. 1997; 42:741-3.
61. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov Today. 2004; 9:697-703.